中国科学院机构知识库网格
Chinese Academy of Sciences Institutional Repositories Grid
Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial

文献类型:期刊论文

作者Huang, Qidan1; Wu, Xiaohua2; Zhu, Jianqing3; Wang, Danqing4; Yang, Jiaxin5; Wang, Jing6; Wu, Lingying7; Liu, Ziling8; Gao, Yunong9; Wang, Danbo10
刊名GYNECOLOGIC ONCOLOGY
出版日期2021-08-01
卷号162
ISSN号0090-8258
资助项目GlaxoSmithKline
WOS研究方向Oncology ; Obstetrics & Gynecology
语种英语
出版者ACADEMIC PRESS INC ELSEVIER SCIENCE
WOS记录号WOS:000687070800027
资助机构GlaxoSmithKline
源URL[http://ir.hfcas.ac.cn:8080/handle/334002/125099]  
专题中国科学院合肥物质科学研究院
作者单位1.Sun Yat Sen Univ, Canc Ctr, Guangzhou, Guangdong, Peoples R China
2.Fudan Univ, Shanghai Canc Ctr, Shanghai, Peoples R China
3.Univ Chinese Acad Sci, Canc Hosp, Beijing, Peoples R China
4.West China Second Univ Hosp, Chengdu, Peoples R China
5.Peking Union Med Coll Hosp, Beijing, Peoples R China
6.Hunan Canc Hosp, Changsha, Peoples R China
7.Chinese Acad Med Sci, Canc Hosp, Beijing, Peoples R China
8.First Hosp Jilin Univ, Changchun, Peoples R China
9.Peking Univ Canc Hosp & Inst, Beijing, Peoples R China
10.China Med Univ, Canc Hosp, Shenyang, Liaoning, Peoples R China
推荐引用方式
GB/T 7714
Huang, Qidan,Wu, Xiaohua,Zhu, Jianqing,et al. Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial[J]. GYNECOLOGIC ONCOLOGY,2021,162.
APA Huang, Qidan.,Wu, Xiaohua.,Zhu, Jianqing.,Wang, Danqing.,Yang, Jiaxin.,...&Dong, Juan.(2021).Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial.GYNECOLOGIC ONCOLOGY,162.
MLA Huang, Qidan,et al."Niraparib maintenance therapy in patients with platinum-sensitive recurrent ovarian cancer and a time-to-progression after penultimate platinum-based chemotherapy of 6-12 or > 12 months: a subgroup analysis of the phase III NORA trial".GYNECOLOGIC ONCOLOGY 162(2021).

入库方式: OAI收割

来源:合肥物质科学研究院

浏览0
下载0
收藏0
其他版本

除非特别说明,本系统中所有内容都受版权保护,并保留所有权利。